NCT04631445 - Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

OTHER

Ketogenic Diet

Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).

Trial Locations (6)

37203

Tennessee Oncology, Nashville

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

85258

Honor Health, Scottsdale

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

06810

Nuvance Health-Danbury Hospital, Danbury

06856

Nuvance Health, Norwalk

All Listed Sponsors

collaborator

Translational Genomics Research Institute

OTHER

lead

Translational Drug Development

OTHER